Clicky

AstraZeneca PLC(AZN) News

Date Title
Oct 23 AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
Oct 22 Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
Oct 21 IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
Oct 21 TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
Oct 20 Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Oct 20 How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Oct 20 IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
Oct 19 Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
Oct 18 Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock
Oct 18 AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
Aug 26 Ken Fisher’s Top 15 Healthcare Stock Picks
Aug 25 AstraZeneca sues US over drug pricing laws
Aug 25 AstraZeneca becomes first international company to file Medicare drug pricing suit
Aug 25 AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan
Aug 25 AstraZeneca files lawsuit against U.S. over drug pricing
Aug 25 AstraZeneca sues US government over drug price reforms
Aug 25 Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation
Aug 25 Midday movers: Affirm, Gap, Marvell Technology and more
Aug 25 AstraZeneca sues US over Medicare drug price negotiation plans
Aug 25 UPDATE 3-AstraZeneca sues US over Medicare drug price negotiation plans